Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

[1]  Janet B W Williams.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[2]  M. Staufenbiel,et al.  The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects , 2011, The Journal of Neuroscience.

[3]  D. Selkoe,et al.  Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.

[4]  D. Morgan.  Immunotherapy for Alzheimer’s disease , 2011, Journal of internal medicine.

[5]  T. Zako,et al.  Amyloid oligomers: formation and toxicity of Aβ oligomers , 2010, The FEBS journal.

[6]  Linus Jönsson,et al.  The worldwide societal costs of dementia: Estimates for 2009 , 2010, Alzheimer's & Dementia.

[7]  E. Masliah,et al.  Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.

[8]  N. Relkin,et al.  18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease , 2009, Neurobiology of Aging.

[9]  M. Sapra,et al.  Anti-amyloid treatments in Alzheimer's disease. , 2009, Recent patents on CNS drug discovery.

[10]  Nick C Fox,et al.  Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders , 2009, Current Alzheimer research.

[11]  T. Wisniewski,et al.  Amyloid-β immunisation for Alzheimer's disease , 2008, The Lancet Neurology.

[12]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[13]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[14]  D. Holtzman,et al.  Active and passive immunotherapy for neurodegenerative disorders. , 2008, Annual review of neuroscience.

[15]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[16]  D. Peabody,et al.  Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. , 2006, Vaccine.

[17]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[18]  I. Ferrer,et al.  Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.

[19]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[20]  C. Cotman,et al.  Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. , 2003, International immunology.

[21]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[22]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[23]  K. Blennow,et al.  Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[24]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[25]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[26]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[28]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[29]  J. Vickers,et al.  Vaccination Strategies for Alzheimer’s Disease , 2007, Drugs & aging.

[30]  K. Blennow,et al.  Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.

[31]  R. Hu.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .